Full Press Release Details
STAAR Surgical Reports Second Quarter
MONROVIA, CA, July 29, 2015---STAAR Surgical Company
(NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye today reported
financial results for the second quarter ended July 3, 2015.
Second Quarter Overview
"Our second quarter results were mixed with strong double
digit ICL unit growth in EMEA and China offset by the weakening euro and yen and continuing softness in Korea" said Caren
Mason, President and CEO. "The impact of the MERS scare in Korea kept patients out of the clinic with cancelled surgeries
and impacted the second traditionally high procedure season this year. In order to capture more of the dollars associated with
our significant unit volume growth, we announced our intent to raise prices on our ICL lenses at our most recent International
Sales and Distributors meeting in Lisbon. The price increase will impact all of our global customers and will be adjusted by market.
It has been several years since we announced a global price increase and many markets have had a strong period of unit growth with
significant investment by STAAR at no additional cost. Most price increases will take effect October 1st in keeping
with notification requirements for contracted customers. During the quarter, we continued our positive momentum in strengthening
manufacturing efficiency and output. Our yields continue to improve and our TICL quarterly shipments were the highest ever recorded
during the second quarter. Importantly, we continue our steadfast commitment and focus on meeting all FDA remediation requirements
and the building of an enhanced Quality System."
Net sales were $18.7 million for the second quarter of 2015,
down 7% compared to $20.0 million reported in the prior year. On a constant currency basis, second quarter net sales declined 3%
compared to the prior period.
The sales decline was driven by
foreign currency changes due to the strengthening U.S. dollar against the euro and the yen, lower IOL unit sales in EMEA, and lower
ICL unit sales primarily in Korea. These impacts were partially offset by ICL unit growth in EMEA of 24% and ICL unit growth in
China of 13%. In the second quarter, 97% of all ICL shipments to China were the CentraFLOW
For the second quarter of 2015, the gross profit margin declined
190 basis points to 66.3% compared to the prior year period of 68.2%. Average unit costs improved 170 basis points but were offset
by a 200 basis point decrease due to the impact of the weaker euro on average selling prices, unfavorable geographic and product
mix of 70 basis points, and 90 basis points in higher other cost of sales.
Operating expenses for the quarter declined 6% to $14.1 million
from $15.1 million in the prior year period, primarily due to lower general and administrative expense, and lower marketing and
selling expense than the prior year period. General and administrative expense was $4.7 million and approximately $632,000 lower
than the prior year due to decreased stock-based compensation and travel costs. Marketing and selling expense was $5.8 million
and approximately $1.2 million lower than the prior year due to decreased stock-based compensation, travel, and promotional costs
and optimization of North American selling costs. Research and development expense, which includes remediation and other FDA expenses,
was $3.5 million and approximately $1.0 million higher than the prior year due to approximately $1.1 million in FDA remediation
expenses in the second quarter of 2015 compared to less than $100,000 in the second quarter of 2014. Remediation costs for the
first half of 2015 are on budget.
The net loss for the second quarter of 2015 was $1.6 million
or $0.04 per share, compared with a net loss of $1.8 million or $0.05 per share for the prior year period.
Adjusted net income for the second quarter of 2015 was $167,000
or breakeven on a per diluted share basis, compared with adjusted net income of $291,000 or $0.01 per diluted share for the prior
year period. The reconciliation between GAAP and non-GAAP financial information is provided in the financial tables included with
Cash and cash equivalents at July 3, 2015 totaled $15.3 million,
compared to $10.8 million at the end of the first quarter of 2015 and $13.0 million at year-end 2014. The Company added $4.5 million
in cash during the second quarter of 2015, which includes $800,000 provided by operating activities, $2.8 million from an exercise
of warrants, and $1.5 million from the exercise of stock options, partially offset by $600,000 in other uses of cash, primarily
purchases of property and equipment.
The Company will host a conference call and webcast on Wednesday,
July 29 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results. To access the conference call (Conference ID
83982418), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants. The live webcast
can be accessed from the investor relations section of the STAAR website at www.staar.com.
A taped replay of the conference call will also be available
beginning approximately one hour after the call's conclusion for seven days. This replay can be accessed by dialing 855-859-2056
for domestic callers and 404-537-3406 for international callers. An archived webcast will also be available at www.staar.com.
Use of Non-GAAP Financial Measures
This press release includes supplemental non-GAAP financial
information, which STAAR believes investors will find helpful in understanding its operating performance.
The Company conducts a significant part of its activities outside
the U.S. It receives sales revenue and pays expenses principally in U.S. dollars, Swiss francs, Japanese yen and Euros. The exchange
rates between dollars and non-U.S. currencies can fluctuate greatly and can have a significant effect on the Company's results
when reported in U.S. dollars. When preparing its financial statements in conformity with GAAP, the Company translates foreign
currency sales and expenses denominated in Japanese yen to dollars at the weighted average of exchange rates in effect during the
period. As a result, the Company's reported performance may be significantly affected by currency fluctuations. In order to compare
the Company's performance from period to period without the effect of currency, the Company will apply the same average exchange
rate applicable in the prior period, or the "constant currency" rate to sales or expenses in the current period as well.
Because changes in currency are outside of the control of the Company and its managers, management finds this non-GAAP measure
useful in determining the long-term progress of its initiatives and determining whether its managers are achieving their performance
goals. The Company believes that the non-GAAP constant-currency sales results measures provided in this press release are similarly
useful to investors to give insight on long term trends in the Company's performance without the external effect of changes in
relative currency values. The table below shows sales results calculated in accordance with GAAP, the effect of currency, and the
resulting non-GAAP measure expressed in constant currency.
"Adjusted Net Income" excludes the following items
that are included in "Net Income" as calculated in accordance with U.S. generally accepted accounting principles ("GAAP"):
manufacturing consolidation expenses, gain or loss on foreign currency transactions, stock-based compensation expenses, and FDA
panel and remediation expenses.
Management believes that "Adjusted Net Income" is
useful to investors in gauging the outcome of the key drivers of the business performance: the ability to increase sales revenue
and our ability to increase profit margin by improving the mix of high value products while reducing the costs over which management
Management has excluded manufacturing consolidation expenses
and FDA panel and remediation expenses because these are non-recurring expenses and their inclusion may mask underlying trends
in our business performance. Expenses associated with the consolidation of the Company's manufacturing operations to the
U.S. were largely completed by the end of the second quarter of 2014.
Management has also excluded gains and losses on foreign currency
transactions because of the significant fluctuations that can result from period to period as a result of market driven factors.
Stock-based compensation expenses consist of expenses for stock
options and restricted stock under the Financial Accounting Standards Board's Accounting Standards Codification (ASC) 718.
In calculating Adjusted Net Income STAAR excludes these expenses because they are non-cash expenses and because of the complexity
and considerable judgment involved in calculating their values. In addition, these expenses tend to be driven by fluctuations in
the price of our stock and not by the same factors that generally affect our other business expenses.
The Company has provided below a detailed reconciliation table,
which is useful to investors in providing the context to understand STAAR Surgical's Adjusted Net Income and how it differs
from Net Income calculated in accordance with GAAP.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery
for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems therefor. All
of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive
surgery as an alternative to LASIK is called an Implantable Collamer Lens or "ICL." A lens used to replace the
natural lens after cataract surgery is called an intraocular lens or "IOL." More than 500,000 Visian ICLs have been
implanted to date. To learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 300 employees and markets lenses
in over 60 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and Monrovia,